Antibody directed against S. aureus clumping factor A (ClfA)
US11970527B2 · kind B2 · utility
0Cited by
12References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 23, 2021 |
| Grant date | Apr 30, 2024 |
| Priority date | — |
| Expiry date | Dec 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.